TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets
David T Yeung(South Australia Pathology), Timothy P. Hughes(South Australia Pathology), Susan Branford(Centre for Cancer Biology), Christopher Arthur(Royal North Shore Hospital), Deborah L. White(ANZCHOG), Constantine S. Tam(The Royal Melbourne Hospital), David M. Ross(South Australia Pathology), Samar Issa(Middlemore Hospital), Jodi Braley(South Australia Pathology), Cecily Forsyth(Gosford Hospital), Yiu Lam Kwan(Concord Repatriation General Hospital), Michael Kornhauser(Peter MacCallum Cancer Centre), Anthony K. Mills(Princess Alexandra Hospital), Devendra Hiwase(Australasian Leukaemia and Lymphoma Group), Mark Hertzberg(The University of Sydney), John Taper(The University of Sydney), Judith Trotman(The University of Sydney), J. Beresford(Peter MacCallum Cancer Centre), Andrew Grigg(The Royal Melbourne Hospital), Anthony P. Schwarer(The Alfred Hospital), Michael Osborn, Robin Filshie(St Vincent's Hospital Melbourne), Alan Herschtal(Peter MacCallum Cancer Centre)
Cited by 102
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
|Journal of Clinical Oncology|2016|867